TrialEBioMedicine2022

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.

Valentina Guarneri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.